Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jul;42(4):e3289.
doi: 10.1002/hon.3289.

A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis

Affiliations
Observational Study

A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis

Claudia Bellofiore et al. Hematol Oncol. 2024 Jul.

Abstract

Daratumumab-based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on the results of the ANDROMEDA study. However, real-world data on daratumumab efficacy in upfront therapy in unselected patients are scanty. In the framework of a prospective observational study, we investigated the efficacy and safety of daratumumab in 88 newly diagnosed patients, including subjects with IIIb cardiac stage (26%) or myeloma defining events (29%). Daratumumab was administered with bortezomib in 50 (56%) patients, lenalidomide in 31 (35%), and monotherapy in 7 (8%). The rate of serious adverse events was low (16%). The overall hematologic response rate was 75% with 52 (59%) patients attaining at least a very good partial response (VGPR) at six months. Amongst patients evaluable for organ response, the rate of cardiac and renal responses at 6 months was 31% and 21%, respectively. Comparing stage IIIb patients with the remaining ones, the rate of profound hematologic response was not significantly different (≥VGPR 57% vs. 59%, p 0.955) likewise the rate of cardiac (33% vs. 30%, p 0.340) and renal (40% vs. 16%, p 0.908) responses. Daratumumab-based regimens demonstrated to be safe and effective in treatment-naïve AL amyloidosis even in advanced stage disease.

Keywords: AL amyloidosis; cardiac staging; daratumumab; prognosis.

PubMed Disclaimer

References

REFERENCES

    1. Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Prim. 2018;4(1):38. https://doi.org/10.1038/s41572‐018‐0034‐3
    1. Palladini G, Schönland S, Merlini G, et al. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023;13(1):19. https://doi.org/10.1038/s41408‐023‐00789‐8
    1. Palladini G, Merlini G. How I treat AL amyloidosis. Blood. 2022;139(19):2918‐2930. https://doi.org/10.1182/blood.2020008737
    1. Wechalekar AD, Cibeira MT, Gibbs SD, et al. Guidelines for non‐transplant chemotherapy for treatment of systemic AL amyloidosis: EHA‐ISA working group. Amyloid. 2022;30:1‐15. Published online. https://doi.org/10.1080/13506129.2022.2093635
    1. Sanchorawala V. Summary of the EHA‐ISA working group guidelines for high‐dose chemotherapy and stem cell transplantation for systemic AL amyloidosis. HemaSphere. 2022;6(2):e681. https://doi.org/10.1097/HS9.0000000000000681

Publication types

MeSH terms

LinkOut - more resources